TrialCancer chemotherapy and pharmacology2015

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).

Masahito Kotaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.